Medicare Enrolled

Dr. Matthew Mavissakalian, D.O.

Allergy & Immunology · Tonawanda, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2540 SHERIDAN DR, Tonawanda, NY 14150
7168748980
In practice since 2013 (13 years)
NPI: 1790028397 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mavissakalian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mavissakalian? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mavissakalian

Dr. Matthew Mavissakalian is an allergy & immunology specialist in Tonawanda, NY, with 13 years of NPI registration. Based on federal Medicare data, Dr. Mavissakalian performed 774 Medicare services across 153 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mavissakalian received a total of $12,296 from 32 pharmaceutical and/or device companies across 428 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in allergy & immunology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mavissakalian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice ▲ 774 Medicare services $12,296 industry payments

Medicare Practice Summary

Medicare Utilization ↗
774
Medicare services
Bottom 31% in NY for allergy & immunology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
153
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~60 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Allergy skin test
A diagnostic test performed to identify specific allergies by applying or introducing allergenic extracts to the body. The procedure measures the patient's immune response to various potential allergens.
375 $3 $10
Skin allergy test
A test where small amounts of potential allergens are injected into the skin to check for allergic reactions.
220 $6 $10
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
64 $56 $100
Allergy injection therapy, multiple injections
A professional service involving the administration of multiple allergen injections.
58 $6 $20
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
57 $26 $75
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$12,296
Total received (2018-2024)
Avg $1,757/year across 7 years
Top 15% in NY for allergy & immunology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
428
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,594 (86.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,647 (13.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$55 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,302
2023
$2,176
2022
$1,344
2021
$1,416
2020
$942
2019
$3,285
2018
$830

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$482
GENZYME CORPORATION
$327
AstraZeneca Pharmaceuticals LP
$318
GlaxoSmithKline, LLC.
$300
Amgen Inc.
$195
PFIZER INC.
$136
CSL Behring
$105
Genentech USA, Inc.
$95
BioCryst US Sales Co., LLC
$84
Takeda Pharmaceuticals U.S.A., Inc.
$75
Pharming Healthcare, Inc.
$70
kaleo, Inc.
$46
Octapharma USA, Inc.
$23
Grifols USA, LLC
$18
Optinose US, Inc.
$16
Mylan Specialty L.P.
$13
Top 3 companies account for 48.9% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$3,417
GlaxoSmithKline, LLC.
$1,305
Regeneron Healthcare Solutions, Inc.
$1,212
AstraZeneca Pharmaceuticals LP
$858
CSL Behring
$725
PFIZER INC.
$466
Takeda Pharmaceuticals U.S.A., Inc.
$415
ALK-Abello, Inc
$371
Amgen Inc.
$357
Genentech USA, Inc.
$348
Optinose US, Inc.
$344
Grifols USA, LLC
$313
Teva Pharmaceuticals USA, Inc.
$275
BioCryst US Sales Co., LLC
$258
Shire North American Group Inc
$254
Pharming Healthcare, Inc.
$253
Boehringer Ingelheim Pharmaceuticals, Inc.
$211
kaleo, Inc.
$182
OptiNose US, Inc.
$150
Kaleo, Inc.
$97
Horizon Therapeutics plc
$96
Incyte Corporation
$79
SANOFI-AVENTIS U.S. LLC
$55
Octapharma USA, Inc.
$44
Novartis Pharmaceuticals Corporation
$42
Hikma Pharmaceuticals USA
$32
Covis Pharma GmBH
$30
USWM, LLC
$29
Mylan Specialty L.P.
$27
BioCryst Pharmaceuticals, Inc.
$18
Bio Products Laboratory USA, Inc.
$17
ABBVIE INC.
$16
Top 3 companies account for 48.3% of all-time payments
Associated products mentioned in payments ›
ACTIMMUNE · AIRSUPRA · ALVESCO · AUVI-Q · AirDuo Digihaler · Auvi-Q · BREZTRI · CIBINQO · CINQAIR · CINRYZE · CUVITRU · DUPIXENT · EOHILIA · EUCRISA · FASENRA · GLASSIA · Gammaplex · Gamunex-C · HYQVIA · Haegarda · Hizentra · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPZELURA · ORLADEYO · Odactra · Orladeyo · Otezla · PANZYGA · ProAir Digihaler · Prolastin-C Liquid · QVAR · RINVOQ · RUCONEST · Ryaltris · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · SYMJEPI · TAKHZYRO · TEZSPIRE · TRELEGY ELLIPTA · XOLAIR · Xembify · Xhance · Xolair · YUPELRI · Yupelri
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an allergy & immunology specialist in Tonawanda?
Compare allergy & immunologists in the Tonawanda area by procedure volume, costs, and industry payment transparency.
Browse allergy & immunologists nearby

Geographic Context

Allergy & immunologists within 10 mi
13
Per 100K population
1.4
County median income
$71,175
Nearest hospital
KENMORE MERCY HOSPITAL
1.8 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Mavissakalian is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 15% of NY peers.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Mavissakalian experienced with allergy skin test?
Based on Medicare claims data, Dr. Mavissakalian performed 375 allergy skin test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mavissakalian receive payments from pharmaceutical companies?
Yes. Dr. Mavissakalian received a total of $12,296 from 32 companies across 428 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mavissakalian's costs compare to other allergy & immunologists in Tonawanda?
Dr. Mavissakalian's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mavissakalian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →